MatchBio

CAR-T therapies have been one of the most transformative advances in oncology over the past decade. But many patients still relapse, and the success of CAR-T therapies has been limited to certain blood cancers, rather than solid tumours.

MatchBio is aiming to engineer the next generation of CAR-T therapies. The company specialises in overcoming a key obstacle in CAR-T cell therapy: the low sensitivity of chimeric antigen receptors (CARs) in detecting cells with diminished antigen expression. MatchBio is developing synthetic CAR constructs engineered to be more sensitive, with the aim of reducing relapse risk, increasing therapeutic safety and expanding the range of detectable tumour antigens.